Company / Operating Cash Flow
LIPELLA PHARMACEUTICALS INC. Operating Cash Flow History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$4.0M
FY2024
5-year range
-$4.0M / -$1.8M
FY2022-FY2024
Trend
-25.4%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$2M to -$4M over the past 2 years.
Based on SEC 10-K filings.
-$4M in FY2024.
Declined from -$2M to -$4M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, operating cash flow decreased 25.4% year-over-year.
Company context
Key Data Points
- Altman Z-Score -8.99 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$4.0M | -25.4% |
| FY2023 | -$3.2M | -72.0% |
| FY2022 | -$1.8M | - |
As of FY2024 · SEC Form 10-K · Last checked Jun 29, 2026